We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK pharma group will continue to lag rivals until litigation risk subsides
UK drugmaker beats forecasts and ‘expects good momentum in 2023’
Drugmaker says new RSV shot appears more effective than rival Pfizer’s candidate
Newly listed consumer health group refuses indemnification requests related to heartburn drug
Technology used to develop Covid vaccines may help in the fight against other diseases
Group developing jab with Sanofi that could have benefits
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
Investors should be wary of the damages a long, drawn out legal battle can inflict
Zantac makers feel the burn
Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs
Investors cool on biggest London listing since Glencore in 2011 on worries about inflation and consumer confidence
Emma Walmsley believes listing of consumer health business will strengthen pharma division
Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
‘Next-generation’ jab delivers strong immune response against variants
Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline
US pharma group to sell down stake in Haleon business after July IPO
Spinning off the business will make more bolt-on deals possible
UK drugmaker to pay $2.1bn upfront plus another potential $1.2bn as it boosts its vaccines business
GSK-controlled company in talks with UN-backed body on generic manufacture of highly effective PrEP injection
UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’
Several hundred staff set stage for first walkout in drugmaker’s history
Sierra’s bone marrow cancer treatment had positive clinical trial results in January
Plus, speculation surrounds Ted Baker, and Russian connections give Jefferies an ESG headache
Drugmaker recoups cash from Moncef Slaoui for non-compliance with company policies
International Edition
